Demand for Advanced Lipids’ infant formula solution soars as tenth anniversary marked

58aff1d2-cd51-499b-a39a-6898aa07b88carticleimage.jpg

04 Dec 2017 --- Demand for infant formula containing Infat SN-2 palmitate – an ingredient that mimics the fatty acid profile in human milk – has soared over the past decade and will continue to grow, according to Advanced Lipids. The company, a joint venture between Enzymotec and AAK, is celebrating its tenth anniversary this year.

Infat was clinically proven in several studies done both in Israel and China to increase fat and calcium absorption, improve bone matrix quality, improve stool consistency and have a positive effect on the development of the intestinal microbiome, Advanced Lipids reports.

Infat was also shown recently to improve babies’ well-being and the quality of life of their parents by reducing crying time and increasing sleep duration, according to the company. NutritionInsight recently reported on a study in the journal Nutrients that linked Infat to healthy bone growth in infants. (link = http://www.nutritioninsight.com/news/Advanced-Lipids-Infat-shows-strong-bone-growth-potential-for-infants.html)

Demand for infant formula rises globally
Advanced Lipids notes that at the end of 2007, when Advanced Lipids was founded, five infant formula brands incorporated Infat. Today, that figure has risen to over 150.

The global market for infant formula has almost tripled since 2006 and currently has a retail value of over US$40 billion, with China accounting for a large percentage of its retail value. Consumers in China place a premium on quality and have high awareness of the benefits of SN-2 palmitate, according to Advanced Lipids.

“In 2007 Enzymotec and AAK made the decision to join forces,” says Ronald van der Knaap, CEO of Advanced Lipids. “As a company that is looking into improving infant nutrition, we saw a great opportunity in this game-changing ingredient that supports formula manufacturers to replicate the benefits of mother’s milk as closely as possible.”

“Over the past decade we’ve been part of huge growth in the infant formula market and witnessed soaring demand for high-end products containing SN-2 palmitate,” Van der Knaap adds.

Advanced Lipids believes regulatory and demographic changes in China will lead to further growth for the formula market, particularly for premium products containing SN-2 palmitate. The recent relaxation of the country’s decades-old single child policy means that it has become a two-child policy, which the company says has sparked a “mini baby boom.” Meanwhile, the company also notes that new market regulations have put greater emphasis on quality.

“Demand for infant formula in China has soared, and the signs we get from the market indicate that growth will continue,” adds Dr. Marcus Gliwitzki, Chairman of Advanced Lipids. “However, companies are now facing a tougher market where consumers and authorities both demand high standards.”

“Over the next ten years, the focus will be on high-quality formula which contains ingredients such as Infat. Advanced Lipids will also put a strong focus on developing innovative Infat solutions in the coming years,” Dr. Gliwitzki concludes.

Related Articles

Nutrition & Health News

BASF targets fatty liver disease with US launch of Hepaxa product

23 Feb 2018 --- BASF is launching Hepaxa to help patients manage non-alcoholic fatty liver disease in what the corporation describes as “the first dedicated product in the US” to potentially assist tens of millions of patients with one of the most common forms of chronic liver disease. And it could begin to “turn around” non-alcoholic fatty liver disease (NAFLD) in as little as six months, according to BASF executives. 

Nutrition & Health News

Pterocarpus marsupium extract found to help lower blood glucose in diabetic rodents

22 Feb 2018 --- Pterocarpus marsupium extracts help lower blood glucose and HbA1c levels, increasing the levels of the hormone insulin in diabetic rats. This is according to a recently published study in the Journal of Dietary Supplements. Manufactured by Sami Labs (the manufacturing arm of Sabinsa Corporation), these extracts contain water-soluble C-glycosidic components and lower oxidative stress and inflammatory markers such as TNF-α, IL-6 (and its mRNA) in diabetic hepatic tissue. 

Nutrition & Health News

Low-carb diet found to help battle fatty liver disease

20 Feb 2018 --- A carbohydrate-restricted diet can lead to “rapid and dramatic” reductions of liver fat and other cardiometabolic risk factors, along with marked decreases in the synthesis of hepatic fat, reveals a study published last week in Cell Metabolism. The study results could lead to improved treatments for non-alcoholic fatty liver disease (NAFLD). 

Nutrition & Health News

Research driving demand for OPO in China’s formula market: Advanced Lipids

16 Feb 2018 --- OPO is increasing in popularity in China’s infant formula market, and according to Advanced Lipids, this is down to the growing body of scientific research backing the benefits of this ingredient. Also known as SN-2 palmitate, OPO is a premium quality ingredient that mimics the fatty acid profile of human milk.

Nutrition & Health News

Bridging the fiber gap: Tereos launches website on dietary fiber

13 Feb 2018 --- Consuming an adequate amount of fiber plays an important role in a wide range of health-related issues, by helping to reduce obesity, improve cholesterol and glycemic index levels and contribute to weight management. To educate consumers about dietary fibers, Tereos has launched a new website, which it says makes it easy to understand the company's Actilight fiber ingredient, its benefits and origin. 

More Articles
URL : http://www.nutritioninsight.com:80/news/demand-for-advanced-lipids-infant-formula-solution-soars-as-tenth-anniversary-marked.html